We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

443 hedge funds and large institutions have $7.39B invested in Abiomed Inc in 2019 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 180 increasing their positions, 148 reducing their positions, and 89 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

22% more repeat investments, than reductions

Existing positions increased: 180 | Existing positions reduced: 148

8% less funds holding

Funds holding: 483443 (-40)

32% less capital invested

Capital invested by funds: $10.9B → $7.39B (-$3.53B)

42% less call options, than puts

Call options by funds: $107M | Put options by funds: $185M

44% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 89

Holders
443
Holders Change
-40
Holders Change %
-8.28%
% of All Funds
9.71%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
50
Increased
180
Reduced
148
Closed
89
Calls
$107M
Puts
$185M
Net Calls
-$77.5M
Net Calls Change
+$46.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$850M +$23.7M +109,413 +2%
BlackRock
2
BlackRock
New York
$577M -$31M -143,426 -4%
Primecap Management
3
Primecap Management
California
$549M -$9.77M -45,200 -1%
Baillie Gifford & Co
4
Baillie Gifford & Co
United Kingdom
$479M +$102M +473,485 +21%
Renaissance Technologies
5
Renaissance Technologies
New York
$380M -$64M -296,000 -12%
State Street
6
State Street
Massachusetts
$352M +$20.1M +93,165 +5%
Sands Capital Management
7
Sands Capital Management
Virginia
$345M -$42.3M -195,596 -9%
BCM
8
Brown Capital Management
Maryland
$289M +$57.9M +268,066 +20%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$137M +$103M +477,638 +164%
William Blair Investment Management
10
William Blair Investment Management
Illinois
$133M -$14.4M -66,717 -8%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$125M +$6.55M +30,281 +5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$121M +$5.03M +23,261 +4%
PAI
13
Palo Alto Investors
California
$116M -$11.2M -51,926 -7%
Franklin Resources
14
Franklin Resources
California
$109M +$5.91M +27,348 +5%
AllianceBernstein
15
AllianceBernstein
Tennessee
$105M +$112M +519,426 +760%
Norges Bank
16
Norges Bank
Norway
$98.7M +$9.02M +41,711 +8%
AAMU
17
Amundi Asset Management US
Massachusetts
$96.3M -$46.6M -215,404 -28%
FAM
18
Fred Alger Management
New York
$95.7M -$4.87M -22,509 -4%
Artisan Partners
19
Artisan Partners
Wisconsin
$86.4M -$4.33M -20,019 -4%
Northern Trust
20
Northern Trust
Illinois
$85.1M +$503K +2,325 +0.5%
WRF
21
Waddell & Reed Financial
Kansas
$81.8M -$33.4M -154,677 -25%
American Century Companies
22
American Century Companies
Missouri
$73.9M -$15.9M -73,749 -15%
Invesco
23
Invesco
Georgia
$61.2M +$8.69M +40,181 +13%
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$57.9M +$15.3M +70,698 +28%
SDJVC
25
St. Denis J. Villere & Co
Louisiana
$54.5M +$15.5M +71,792 +31%

ABMD Hedge Fund Activity: Q3 2019 in Review

443 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2019, worth a combined $7.39B — down 32% from $10.9B a quarter earlier.

Sellers outnumbered buyers: 89 funds closed out of ABMD and 50 opened new positions — a net loss of 39 holders — while 148 trimmed existing stakes and 180 added.

The largest buyer was AllianceBernstein, adding an estimated $112M. The largest seller was Renaissance Technologies, cutting an estimated $64M.

  • 443 institutional investors held Abiomed Inc (ABMD) as of Q3 2019, down from 483 in Q2 2019.
  • Funds reported $7.39B of Abiomed Inc stock for Q3 2019, down 32% quarter-over-quarter.
  • 50 funds opened new Abiomed Inc positions in Q3 2019 and 89 closed out, a net change of -39 holders.
  • The largest Abiomed Inc buyer in Q3 2019 was AllianceBernstein, an estimated $112M added.
  • The largest Abiomed Inc seller in Q3 2019 was Renaissance Technologies, an estimated $64M sold.

Based on aggregated 13F filings for Q3 2019.